

Mar. 13. 2008 3:27PM Farsight Patents (650)-679-9596

No. 0046 P. 8

01/25/2008 14:00 6507809030

FARSIGHT/HIGH TECHNI

PAGE 04/08

RECEIVED  
CENTRAL FAX CENTER  
JAN 25 2008

Intarcia Dkt No. AJE 053.16  
USSN: 10/645,293  
PATENT

**CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)**

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.

*Greg R. Talar*  
Signature

1/25/2008  
Date of Transmittal

RECEIVED  
CENTRAL FAX CENTER

MAR 13 2008

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: PEERY, John, et al.	Confirmation No.: 7202
Serial No.: 10/645,293	Art Unit: 1618
Filing Date: 20 August 2003	Examiner: Ebrahim, N.G.

Title: SUSTAINED DELIVERY OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM

**REVOCATION AND SUBSTITUTE POWER OF ATTORNEY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This application is a continuation of U.S. Patent Application No. 10/108,303, filed 03-28-2002, now U.S. Patent No. 6,635,268, which is a continuation of U.S. Patent Application No. 09/848,211, filed 05-04-2001, now U.S. Patent No. 6,395,292, which is a continuation of U.S. Patent Application No. 09/366,746, filed 08-04-1999, now U.S. Patent No. 6,261,584, which is a continuation of U.S. Patent Application No. 08/943,007, filed 10-02-1997, now U.S. Patent No. 5,985,305, which is a continuation of U.S. Patent Application No. 08/791,699, filed 01-30-1997, now U.S. Patent No. 5,728,396.

The undersigned has reviewed all the documents in the chain of title pursuant to 37 C.F.R. §3.73, and to the best of the undersigned's knowledge, Intarcia Therapeutics, Inc., is the assignee of the entire right, title, and interest in this application, specifically: the assignment recorded on 01/30/1997 at Reel/Frame 008540/0624, and the assignment recorded on 12/13/2007 at Reel/Frame 020252/0143.

Intarcia Therapeutics, Inc., hereby revokes all powers of attorney previously given and hereby appoints the following attorney and agent to prosecute this application and to make

Mar. 13. 2008 3:28PM Farsight Patents (650)-679-9596

No. 0046 P. 9

01/25/2008 14:00 6507809030

FARSIGHT/HIGH TECHNI

PAGE 05/08

RECEIVED  
CENTRAL FAX CENTER  
MAR 13 2008

RECEIVED  
CENTRAL FAX CENTER  
JAN 25 2008

Intarcia Dkt No. ALE 053.16  
USSN: 10/645,293  
PATENT

alterations and amendments therein. Each of the following attorney and agent has full power of substitution and revocation:

Barbara G. McClung (Registration No. 33,113) Gary R. Fabian (Registration No. 33,875)

Please direct all future correspondences in connection with this application to:

Customer Number: 000074866

Barbara G. McClung, Esq.  
Vice President, General Counsel and Corporate Secretary  
Intarcia Therapeutics, Inc.  
2000 Powell Street  
Suite 1640  
Emeryville, CA 94608  
Phone: (510) 652-2600  
Fax: (510) 652-2657


No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 504212 (please reference docket number ALE 053.16) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,

Dated: 1/17/08

By:

  
Barbara G. McClung, Esq.  
Vice President, General Counsel and  
Corporate Secretary  
Intarcia Therapeutics, Inc.  
Registration No. 33,113

Intarcia Therapeutics, Inc.  
2000 Powell Street  
Suite 1640  
Emeryville, CA 94608  
Phone: (510) 652-2600  
Fax: (510) 652-2657